Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isogambogenic acid (iso-GNA) is a naturally occurring xanthone and an isomer of gambogenic acid, typically isolated from the resin of the *Garcinia hanburyi* tree. It is being investigated for its potent antineoplastic properties, particularly in the context of non-small cell lung carcinoma (NSCLC). Unlike many conventional chemotherapeutic agents that trigger apoptosis, isogambogenic acid has been shown to induce apoptosis-independent autophagic cell death. This process is characterized by the formation of autophagic vacuoles, increased conversion of LC3-I to LC3-II, and the upregulation of key autophagy-related proteins such as Atg7 and Beclin 1. Its ability to bypass apoptosis makes it a candidate for treating cancers that have developed resistance to traditional apoptosis-inducing drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isogambogenic acid.